(19)
(11) EP 4 522 613 A1

(12)

(43) Date of publication:
19.03.2025 Bulletin 2025/12

(21) Application number: 23731061.0

(22) Date of filing: 10.05.2023
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
C07D 519/00(2006.01)
A61K 31/519(2006.01)
C07D 487/04(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 487/04; C07D 471/04; C07D 519/00; A61P 35/00
(86) International application number:
PCT/US2023/066834
(87) International publication number:
WO 2023/220640 (16.11.2023 Gazette 2023/46)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 10.05.2022 US 202263364470 P
06.10.2022 US 202263378671 P
14.04.2023 US 202363496380 P

(71) Applicant: Biotheryx, Inc.
San Diego, California 92121 (US)

(72) Inventors:
  • CHOURASIA, Aparajita Hoskote
    San Diego, California 92129 (US)
  • ERDMAN, Paul E.
    San Diego, California 92126 (US)
  • FUNG, Leah M.
    San Diego, California 92129 (US)
  • HUANG, Shenlin
    San Diego, California 92130 (US)
  • LAM, Imelda
    San Diego, California 92131 (US)
  • MAJESKI, Hannah
    San Diego, California 92116 (US)
  • OKANO, Akinori
    San Diego, California 92126 (US)
  • PAPA, Patrick
    Carlsbad, California 92008 (US)
  • SAPIENZA, John
    Vista, California 91913 (US)
  • TORRES, Eduardo
    San Diego, California 92102 (US)
  • WHITEFIELD, Brandon
    San Diego, California 92108 (US)

(74) Representative: Maiwald GmbH 
Grünstraße 25
40212 Düsseldorf
40212 Düsseldorf (DE)

   


(54) CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS